Abbott Laboratories (ABT) Rated Buy as Benchmark Highlights Diagnostics Growth and Global Resilience
Abbott Laboratories (NYSE:ABT) ranks among the best medical device stocks to invest in.
Abbott Laboratories (ABT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lee Munder Capital Group Lee Munder | 139,713 | $18,713,208 | -3% | 1.1% |
| 2. | Ayrshire Capital Management John Nevin Jr. | 37,671 | $5,045,620 | -5% | 2.34% |
| 3. | Zevenbergen Capital Investments Nancy Zevenbergen | 21,124 | $2,829,349 | +1% | 0.06% |
| 4. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 10,950 | $1,466,643 | 0.69% | |
| 5. | RWC Asset Management Tord Stallvik (Ceo) | 2,398 | $321,188 | +39% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.50 | 2,040 | $249,900.00 | 7,296 | 2021-02-23 | Filing | |
| $73.40 | 2,000 | $146,798.20 | 52,562 | 2019-04-22 | Filing | |
| $72.32 | 100 | $7,231.50 | 6,400 | 2019-01-31 | Filing | |
| $72.31 | 100 | $7,230.50 | 6,300 | 2019-01-31 | Filing | |
| $72.33 | 1,800 | $130,194.00 | 6,200 | 2019-01-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $134.55 | 5,550 | $746,758.05 | 51,003 | 2025-08-08 | Filing | |
| $129.66 | 2,600 | $337,116.00 | 34,058 | 2025-04-30 | Filing | |
| $136.65 | 200 | $27,329.00 | 71,928 | 2025-03-07 | Filing | |
| $133.82 | 91,167 | $12,199,967.94 | 71,928 | 2025-03-06 | Filing | |
| $138.17 | 949 | $131,123.33 | 74,381 | 2025-03-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 15,096,907 | $2,022,079,724 | 0.63% | |
| 2. | 4,975,638 | $666,436,955 | 2.01% | |
| 3. | 4,190,759 | $561,310,260 | 0.32% | |
| 4. | 2,158,089 | $289,054,440 | 1.59% | |
| 5. | 1,669,794 | $210,961,936 | 1.85% |
News See All
12 Best Medical Device Stocks to Invest In Now
As chronic diseases like diabetes and cancer become more common, medical device technology is becoming increasingly innovative.
Abbott Laboratories (NYSE:ABT) Q3 2025 Earnings Call Transcript
Operator: Good morning, and thank you for standing by. Welcome to Abbott Laboratories' Third Quarter 2025 Earnings Conference Call.
19 Stocks in Jim Cramer's Game Plan For This Week
“Now, we bought a little bit of stock, not a lot, for the Charitable Trust today, and we only did so because there could be some of that art of the deal thing going on.
Abbott Laboratories (ABT): A Healthcare Leader Powering the List of Profitable Dividend Stocks
Abbott Laboratories (NYSE:ABT) has long been a household name in the healthcare world, offering products that reach millions of people every day.
13 Most Profitable Dividend Stocks to Buy Right Now
In a period marked by market volatility, ongoing policy and geopolitical uncertainty, many investors have been shifting toward fixed-income assets and away...
Abbott Laboratories (ABT) Maintains Strong MedTech Growth Outlook
Abbott Laboratories (NYSE:ABT) ranks among the top picks for a retirement portfolio.
Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale
Abbott Laboratories (NYSE:ABT) reported a 6.9% increase in sales for the second quarter of 2025.
Retirement Stock Portfolio: Top 15 Stock Picks
The Federal Reserve is decreasing its benchmark rate after holding them stable for most of the year despite President Donald Trump's demands to do so.
12 Set-It-and-Forget-It Stocks to Buy Now
Inflation continues a downward trend, and the Federal Reserve has signaled the possibility of a looser monetary policy, making the emerging new market environment a favorable one for long-term investors...
Hedge Fund Resource Center Billionaire Hedge Funds
